Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
about
Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary diseaseShared genetic susceptibility of vascular-related biomarkers with ischemic and recurrent strokeAssociation of statin use with cognitive decline in elderly African Americans.Vitamin C treatment reduces elevated C-reactive proteinStatins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins.The Anti-Inflammatory Actions of Exercise TrainingIntegrative Treatments to Reduce Risk for Cardiovascular DiseaseAssociation between obesity, high-sensitivity C-reactive protein ≥2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis.Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adultsInflammation biomarkers and risk of all-cause mortality in the Reasons for Geographic And Racial Differences in Stroke cohort.Influence of pericoronary adipose tissue on local coronary atherosclerosis as assessed by a novel MDCT volumetric method.The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA).Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United StatesOn-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: aPre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort StudyAnalysis of National Pharmacovigilance Data Associated with Statin Use in Korea.Cholesterol and 24S-hydroxycholesterol trafficking in Alzheimer's disease.Review article: The role of statins in reducing perioperative cardiac risk: Physiologic and clinical perspectives.Cardiovascular disease, inflammation, and periodontal infection.Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?C-reactive protein in cardiovascular risk assessment: a review of the evidence.Human cholesterol metabolism and therapeutic molecules.Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: a population-based register studyEfficacy and safety of rosuvastatin in the management of dyslipidemiaAn Evaluation of the Clinical Evidence on the Role of Inflammation and Oxidative Stress in Smoking-Mediated Cardiovascular Disease.Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY StudyThe Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy.Hypertensive disorders of pregnancy: preventative-, immediate- and long-term management.Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target.Pathogenesis of postoperative adhesion formation.Lipids and diabetic retinopathy.Clinical utility of novel biomarkers for cardiovascular disease risk stratification.Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges.Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit.Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries.Association of Neutrophil-Lymphocyte Ratio and the Presence of Noncalcified or Mixed Coronary Atherosclerotic Plaques.Point-of-care diagnostics: market trends and growth drivers.High-density lipoprotein cholesterol, C-reactive protein, and prevalence and severity of coronary artery disease in 5641 consecutive patients undergoing coronary angiography.
P2860
Q29416995-3A9E9712-3B62-486C-8848-2B59DF308AE7Q30277827-3ED8E0B1-C15E-4E7C-A8AC-5A4CED53A94DQ33802886-74D04236-72EB-41DA-B664-6E5A7408EBAEQ34014359-CAFEAE76-F99F-4DC0-A752-E71AA7AEC6E0Q34429685-2F9AA405-064D-478E-BF94-087C08CED949Q34569544-AEFADA87-FE8F-4937-8298-0583B1CE4FCAQ34730309-6E2FCFDF-ADA4-49F7-9A0D-2D36B0EAC00EQ35088117-56AB07AB-F5ED-48D2-88CF-60AAF76307D7Q35243077-AE813FD8-DA1E-4B23-AF58-167D305D10B3Q35450611-ABB3A1AB-681B-46C8-8BD8-3D6ED1E8F0CCQ35465381-02AABA7A-78BA-4AC6-9C49-09C1F55B8615Q35525608-A37094FD-ABE8-45D2-ACA4-97E52E4E60A7Q35683097-8DD48151-FF8F-48EC-A973-40E17BDC7815Q35917224-F65FB172-24A8-4BC5-99F2-242A37C7E81AQ36068935-C0AD098E-2184-4C44-A750-C77DD0DC39BBQ36370933-5608C38E-F4B3-436A-87A5-FF3052FC0067Q36492343-CC6962E0-2790-4C83-9504-C9328CA194FAQ36641901-49E919F7-B865-4CFF-A012-03EEDBB76172Q36809182-75F22001-D7E2-4E72-9E26-7D590B7DBD3EQ36847283-27915FD4-3A58-4188-9D47-105CF582CAB6Q36904449-77552D92-EA10-498A-A6B9-CCE5660649C8Q37047547-94A05A9B-A1D8-4671-9A1D-BC9BFAC89780Q37113316-9A5B0774-642D-4AD8-82F4-410525A4F3EBQ37167517-66007B9A-BA91-4C4F-9CF6-0DDF9003D47AQ37207355-1928A087-38F8-4585-A309-DDB8064699BDQ37299877-2D023491-FA19-445E-9540-4DE56CC0D606Q37491763-8515BB43-B276-4B92-A815-165329FE8C3EQ37671955-5C21399D-FD39-4423-AB26-20BA00E6F926Q37763163-41CEC5FE-8024-41AA-B79B-4BA41ACDC248Q37851481-D74DB689-84A3-4E2D-BB9C-D6D6346828FAQ37878492-561CE007-C231-4331-90F2-2727426FFBF6Q37923882-0051CE70-CC3B-4591-A39F-5D875A9252FEQ37961883-D10283AA-966B-4F8B-8066-9911DE0C269FQ38052852-EE678527-CA59-415D-BEA4-8F580706B432Q38066413-7FFACD38-F7DC-45A7-B299-B95D8A2C4324Q38256054-7AECA755-6DC0-43FF-9E4B-8B671D110F89Q38450680-6919A61A-36BC-4F8E-A03D-A29C15C72D8FQ38691554-DDBCB5E1-BF42-4B86-93A7-E0062D434088Q40013851-B85F8B89-DC03-40CA-A82E-63CAF6A5D410Q40090236-8115CDFD-99F4-42E8-A448-29C3E8E0974D
P2860
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Justification for the Use of S ...... therapy in primary prevention?
@ast
Justification for the Use of S ...... therapy in primary prevention?
@en
type
label
Justification for the Use of S ...... therapy in primary prevention?
@ast
Justification for the Use of S ...... therapy in primary prevention?
@en
prefLabel
Justification for the Use of S ...... therapy in primary prevention?
@ast
Justification for the Use of S ...... therapy in primary prevention?
@en
P1476
Justification for the Use of S ...... therapy in primary prevention?
@en
P2093
Paul M Ridker
Samia Mora
P304
P356
10.1016/J.AMJCARD.2005.11.014
P407
P577
2005-12-01T00:00:00Z